Lateral flow assay (LFA) based on gold nanoparticles
(AuNPs) is
a widely used analytical device for the rapid analysis of environmental
hazards and biomarkers. Typically, a sandwich-type format is used
for macromolecule detection, in which the appearance of a red test
line indicates a positive result (Signal-ON). In contrast, small molecule
detection usually relies on a competitive assay, where the absence
of a test line indicates positive testing (Signal-OFF). However, such
a “Signal-OFF” reading is usually detected within a
narrower dynamic range and tends to generate false-negative signals
at a low concentration. Moreover, inconsistent readings between macromolecule
and small molecule testing might lead to misinterpretation when used
by nonskilled individuals. Herein, we report a “Signal-ON”
small molecule competitive assay based on the sterically modulated
affinity-switchable interaction of biotin and streptavidin. In the
absence of a small molecule target, a large steric hindrance can be
imposed on the biotin to prevent interaction with streptavidin. However,
in the presence of the small molecule target, this steric effect is
removed, allowing the biotin to bind to streptavidin and generate
the desired test line. In this article, we demonstrate the selective
detection of two small molecule drugs, sulfonamides and trimethoprim,
using this simple and modular affinity-switchable lateral flow assay
(ASLFA). We believe that this affinity-switchable approach can also
be adapted in drug discovery and clinical diagnosis, where the competitive
assay format is always used for the rapid analysis of small molecules.